Scarica l'app Stockscreener
16.71
0.12%
0.02
Pre-mercato:
16.51
-0.20
-1.20%
Precedente Chiudi:
$16.69
Aprire:
$16.61
Volume 24 ore:
386.15K
Relative Volume:
0.89
Capitalizzazione di mercato:
$861.45M
Reddito:
$109.78M
Utile/perdita netta:
$114.54M
Rapporto P/E:
7.5796
EPS:
2.2046
Flusso di cassa netto:
$268.74M
1 W Prestazione:
+2.08%
1M Prestazione:
+3.02%
6M Prestazione:
-6.70%
1 anno Prestazione:
+57.64%
Intervallo 1D:
$16.52
$16.81
Intervallo di 1 settimana:
$16.21
$16.81
Portata 52W:
$10.44
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.71 | 841.35M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2026-03-04 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2025-12-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-12 | Iniziato | B. Riley Securities | Buy |
| 2024-08-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | Iniziato | BTIG Research | Buy |
| 2024-01-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
13,314 restricted shares listed for sale by TBPH (NASDAQ: TBPH) — Rule 144 notice - Stock Titan
Theravance Biopharma, Inc. 8-K Filing Details: Annual Meeting Results, Auditor Appointment, and Company Information (June 2026) - Minichart
Theravance Biopharma Shareholders Back Directors and Governance Plans - TipRanks
Theravance Biopharma (NASDAQ: TBPH) investors approve directors, auditor and pay plan - Stock Titan
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Theravance stock declines around 17% in three months: Here's why - MSN
Jones Trading Initiates Coverage of Theravance Biopharma (TBPH) with Buy Recommendation - MSN
TBPH Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineRevenue Surprise History - newsline.com
Avoiding Lag: Real-Time Signals in (TBPH) Movement - Stock Traders Daily
Theravance Biopharma (TBPH) Edges Lower Amid Mixed Technical Signals – Key Levels to MonitorEarnings Beat Stocks - newsline.com
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19 - Moomoo
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19 - TipRanks
Discipline and Rules-Based Execution in TBPH Response - Stock Traders Daily
Theravance Biopharma (TBPH) CEO has shares withheld to cover RSU taxes - Stock Titan
Theravance Biopharma (NASDAQ: TBPH) CFO has 8,670 shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has shares withheld for RSU taxes - Stock Titan
Theravance Biopharma (TBPH) SVP has 8,829 shares withheld for RSU tax - Stock Titan
Theravance Biopharma (TBPH) SVP uses 5,678 shares to cover tax bill - Stock Titan
Theravance Biopharma (TBPH) Q4 earnings and revenues lag estimates - MSN
Behavioral Patterns of TBPH and Institutional Flows - Stock Traders Daily
TradingKey - TradingKey
Are Options Traders Betting on a Big Move in Theravance Biopharma Stock? - TradingView
BTIG Maintains Theravance Biopharma (TBPH) Buy Recommendation - MSN
Here's why Theravance Biopharma (TBPH) is a strong momentum stock - MSN
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle - sharewise.com
BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and Strategic Collaborations Point to Promising Future - DirectorsTalk Interviews
Theravance Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q1 Revenue $17.7M, vs. FactSet Est of $17.8M - marketscreener.com
Theravance Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Theravance Biopharma (NASDAQ: TBPH) slashes R&D after ampreloxetine trial miss - Stock Titan
Theravance Biopharma reports Q1 2026 revenue $17.7M, narrows net loss to $4.9M - TradingView
Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth - TradingView
Theravance Bio: Q1 Earnings Snapshot - KTVB
Theravance (NASDAQ: TBPH) targets $60–70M cash flow after major restructuring - Stock Titan
Theravance Biopharma: Confident Will Achieve $100 Million Milestone Payment Associated With 2026 Trelegy Net Sales >TBPH - Moomoo
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - ChartMill
MSN Money - MSN
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Theravance's Q4 earnings and revenues miss estimates - MSN
Theravance Biopharma (NASDAQ:TBPH) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Theravance Biopharma Inc Azioni (TBPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Mar 16 '26 |
Sale |
13.96 |
31,067 |
433,637 |
232,699 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):